124 related articles for article (PubMed ID: 26786917)
1. Reply to A. Indini et al.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2016 Mar; 34(9):1018-9. PubMed ID: 26786917
[No Abstract] [Full Text] [Related]
2. Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.
Indini A; Di Nicola M; Del Vecchio M; De Braud F
J Clin Oncol; 2016 Mar; 34(9):1017-8. PubMed ID: 26786928
[No Abstract] [Full Text] [Related]
3. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
Koch C; Paetzold S; Trojan J
Gastroenterology; 2012 Aug; 143(2):298, 504, 505. PubMed ID: 22709738
[No Abstract] [Full Text] [Related]
4. Melanoma and a Headache. Diagnosis: Hypophysitis.
Johnson DB; Mudigonda TV; Sosman JA
JAMA Oncol; 2015 Nov; 1(8):1167-8. PubMed ID: 26225893
[No Abstract] [Full Text] [Related]
5. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.
Matsumura N; Ohtsuka M; Kikuchi N; Yamamoto T
Acta Derm Venereol; 2016 Feb; 96(2):259-60. PubMed ID: 26270860
[No Abstract] [Full Text] [Related]
6. Polymyalgia rheumatica occurring during treatment with ipilimumab.
Maniu C; Kobe C; Schlaak M; Mauch C; Eming SA
Eur J Dermatol; 2016 Oct; 26(5):513-514. PubMed ID: 27349150
[No Abstract] [Full Text] [Related]
7. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.
Maur M; Tomasello C; Frassoldati A; Dieci MV; Barbieri E; Conte P
J Clin Oncol; 2012 Feb; 30(6):e76-8. PubMed ID: 22203769
[No Abstract] [Full Text] [Related]
8. Novel melanoma therapies and their side effects.
González N; Ratner D
Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
[TBL] [Abstract][Full Text] [Related]
9. Rare heart risk found with checkpoint inhibitors.
Printz C
Cancer; 2017 May; 123(9):1483-1484. PubMed ID: 28430361
[No Abstract] [Full Text] [Related]
10. Nursing management of patients with metastatic melanoma receiving ipilimumab.
Bryce J; Passoni C
Oncol Nurs Forum; 2013 May; 40(3):215-8. PubMed ID: 23615135
[No Abstract] [Full Text] [Related]
11. Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?
Loricera J; Hernández JL; García-Castaño A; Martínez-Rodríguez I; González-Gay MÁ; Blanco R
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):171. PubMed ID: 29799390
[No Abstract] [Full Text] [Related]
12. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
[No Abstract] [Full Text] [Related]
14. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
15. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
Beniwal-Patel P; Matkowskyj K; Caldera F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
[No Abstract] [Full Text] [Related]
16. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.
Schneiderbauer R; Schneiderbauer M; Wick W; Enk AH; Haenssle HA; Hassel JC
Acta Derm Venereol; 2017 Mar; 97(3):395-396. PubMed ID: 27868138
[No Abstract] [Full Text] [Related]
17. First report of ipilimumab-induced Grover disease.
Munoz J; Guillot B; Girard C; Dereure O; Du-Thanh A
Br J Dermatol; 2014 Nov; 171(5):1236-7. PubMed ID: 24749658
[No Abstract] [Full Text] [Related]
18. [A new form of hypophisitis following ipilimumab therapy].
Schmutz JL
Ann Dermatol Venereol; 2015 Apr; 142(4):307-8. PubMed ID: 25770731
[No Abstract] [Full Text] [Related]
19. Vemurafenib sensitivity skin reaction after ipilimumab.
Harding JJ; Pulitzer M; Chapman PB
N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
[No Abstract] [Full Text] [Related]
20. Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events.
Iwamoto K; Ishitsuka Y; Tanaka R; Sekine I; Fujimoto M
Eur J Dermatol; 2017 Jun; 27(3):301-303. PubMed ID: 28468733
[No Abstract] [Full Text] [Related]
[Next] [New Search]
